Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, continuous, hormone therapy, intermittent, outcome, survival | 5 Comments »
Acccording to an article on the Medscape web site today, the convicted “Lockerbie bomber,” Abdelbaset al Megrahi, finally died on Sunday, 2 years and 9 months after his release from a Scottish prison on compassionate grounds because he was close to dying of terminal prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, al Megrahi, survival | 9 Comments »
A new review published recently in the British Journal of Cancer addresses appropriate current practice regarding the use of neoadjuvant and adjuvant androgen deprivation therapy (ADT) in combination with radiation therapy in the management of patients with high-risk localized and locally advanced forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, androgen deprivation, localized, locally advanced, outcomes, radiation therapy, survival | 4 Comments »
Data from the extensive series of patients with clinically localized prostate cancer treated by radical prostatectomy at Johns Hopkins over the past 30 years has shown that men > 65 years of age with low-risk disease had excellent survival after surgery, … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: age, low risk, outcome, radical prostatectomy, survival | 1 Comment »
A new study in the Journal of Clinical Oncology has provided data regarding the survival of men of 65 years and older diagnosed with and treated for selected cancers within the Veterans Health Administration (VHA) system as compared to similar men treated under the fee-for-service Medicare system. This study has received a lot of media coverage. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: comparison, fee for service, Medicare, survival, Veterans Administration | Leave a Comment »
A newly published article has concluded that, among the 4,000+ men enrolled in the Spanish cohort of the European Randomized Study of Screening for Prostate Cancer (ERSPC), there were no differences in overall or prostate cancer-specific mortality at 15 years of follow-up. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: benefit, outcome, screening, survival | 6 Comments »
For many men, a diagnosis of prostate cancer of any stage or grade — even of the lowest level of risk — is hard to deal with. If they have progressive disease after first-line therapy, it may appear to be an overwhelming issue. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Uncategorized | Tagged: advanced, hope, outcome, survival | 3 Comments »
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a Comment »
A new study on relative rates of survival at 10 years, just published on line, is probably going to get differing reactions from patients and from physicians depending on their individual points of view. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: comparative, mortality, outcome, survival | 10 Comments »
Whatever we may think individually about the recent decision by the U.S. Preventive Services Task Force to recommend against the use of PSA testing as a means of “screening” for risk of prostate cancer, we would be wise to understand that at the heart of this decision is poor science. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: PSA, risk, screening, survival, USPSTF | 29 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site